OT mobile menu



MEK Inhibitor for Thyroid Cancer

Selumetinib may become a treatment option for stage III/IV differentiated thyroid cancer. Image © Nerthuz/Shutterstock.com 

Recent Content

Along with gene expression signatures from a 15-loci panel, tumor diameter and specific driver mutations predict metastasis risk and survival among patients with uveal melanoma.

Compared to everolimus, the oral tyrosine kinase inhibitor cabozantinib improves objective tumor response, delays disease progression, and prolongs overall survival time among patients with RCC.

In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.

Inflammatory arthritis and sicca syndrome appear to be immune-related adverse events among some patients undergoing cancer treatment with the immune checkpoint inhibitors nivolumab and ipilimumab.

Researchers published a study June 12, 2016, in the online issue of The New England Journal of Medicine that suggests progression-free survival and overall survival may both be longer with inotuzumab ozogamicin in ALL.

In this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.

Molecular imaging of tumor glucose metabolism might be a prognostic biomarker of NSCLC responses to the investigational immunotherapy agent atezolizumab.

By clicking Accept, you agree to become a member of the UBM Medica Community.